Transaction #23988 · Form 4 · 0001221355-25-000005
Allogene Therapeutics, Inc. · Exercise / conversion · Common Stock
Allogene Therapeutics, Inc. · Transacted December 18, 2025 · Filed December 22, 2025
What does this filing report?
An SEC Form 4 filing for Allogene Therapeutics, Inc. records an exercise / conversion involving Common Stock on December 18, 2025. The reported quantity was 47,700. The filing date is December 22, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Allogene Therapeutics, Inc.
- Company CIK
- 0001737287
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 47,700
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 350,763
- Ownership description
- Not reported
- SEC acceptance time
- Dec 22, 2025, 6:57 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Kazam Joshua A ↗
Director
CIK 0001221355
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- On June 23, 2025, this grant was erroneously reported as 94,500 shares and is corrected here upon the vesting of the first of the semi-annual installments.
- F2
- Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2018 Plan.
- F3
- Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.